Clorox (NYSE:CLX) PT Lowered to $132.00 at Deutsche Bank Aktiengesellschaft

Clorox (NYSE:CLXGet Rating) had its target price trimmed by Deutsche Bank Aktiengesellschaft from $145.00 to $132.00 in a research note issued to investors on Tuesday morning, The Fly reports.

A number of other analysts have also weighed in on the stock. StockNews.com assumed coverage on shares of Clorox in a research report on Thursday, March 31st. They issued a hold rating on the stock. Wells Fargo & Company upped their target price on shares of Clorox from $120.00 to $130.00 in a research note on Tuesday, May 3rd. Barclays dropped their target price on shares of Clorox from $126.00 to $115.00 and set an underweight rating on the stock in a research note on Monday, May 23rd. The Goldman Sachs Group dropped their target price on shares of Clorox from $145.00 to $127.00 in a research note on Tuesday, March 29th. Finally, JPMorgan Chase & Co. upped their target price on shares of Clorox from $123.00 to $126.00 in a research note on Thursday, April 14th. Nine equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Reduce and a consensus price target of $140.69.

Shares of NYSE CLX opened at $140.11 on Tuesday. The firm’s 50-day moving average price is $142.50 and its 200-day moving average price is $151.47. The company has a current ratio of 0.71, a quick ratio of 0.40 and a debt-to-equity ratio of 3.28. The stock has a market capitalization of $17.24 billion, a price-to-earnings ratio of 37.97, a P/E/G ratio of 4.31 and a beta of 0.18. Clorox has a 12-month low of $120.50 and a 12-month high of $191.75.

Clorox (NYSE:CLXGet Rating) last announced its earnings results on Monday, May 2nd. The company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $0.34. The firm had revenue of $1.81 billion for the quarter, compared to analysts’ expectations of $1.81 billion. Clorox had a net margin of 6.44% and a return on equity of 92.98%. During the same period in the prior year, the company earned $1.62 EPS. On average, equities analysts predict that Clorox will post 4.16 EPS for the current fiscal year.

In related news, COO Eric H. Reynolds sold 585 shares of the business’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $154.83, for a total transaction of $90,575.55. Following the transaction, the chief operating officer now directly owns 17,289 shares in the company, valued at $2,676,855.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director A D. David Mackay sold 1,000 shares of Clorox stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $140.63, for a total transaction of $140,630.00. Following the transaction, the director now directly owns 600 shares in the company, valued at $84,378. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dark Forest Capital Management LP acquired a new position in shares of Clorox in the 3rd quarter valued at $25,000. Newbridge Financial Services Group Inc. grew its stake in Clorox by 185.2% in the 4th quarter. Newbridge Financial Services Group Inc. now owns 154 shares of the company’s stock valued at $27,000 after acquiring an additional 100 shares during the last quarter. TAP Consulting LLC acquired a new stake in Clorox in the 4th quarter valued at about $27,000. FSB Premier Wealth Management Inc. acquired a new stake in shares of Clorox during the 4th quarter worth about $28,000. Finally, Financial Avengers Inc. boosted its position in shares of Clorox by 119.7% in the fourth quarter. Financial Avengers Inc. now owns 167 shares of the company’s stock worth $29,000 after acquiring an additional 91 shares during the last quarter. 77.28% of the stock is currently owned by hedge funds and other institutional investors.

About Clorox (Get Rating)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brand names; professional cleaning and disinfecting products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brand names; professional food service products under the Hidden Valley brand name; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brand names in the United States.

Recommended Stories

The Fly logo

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.